Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0K0TC
|
|||
| Former ID |
DAP000051
|
|||
| Drug Name |
Sertraline
|
|||
| Synonyms |
Lustral; SRE; Sertralina; Sertralinum; Sertralina [Spanish]; Sertraline [Zoloft]; Sertralinum [Latin]; CP 51974; Cp 51974; Apo-Sertraline; Lustral (TN); Sertraline (INN); Sertraline (Zoloft); Sertraline [INN:BAN]; Zoloft (TN); (+)-Sertraline; (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine; (1S-cis)-1,2,3,4-Tetrahydro-4-(3,4-dichlorophenyl)-N-methyl-1-naphthalenamine; (1S-cis)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthalenamine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Depression [ICD-11: 6A70-6A7Z; ICD-9: 311] | Approved | [1], [2] | |
| Therapeutic Class |
Antidepressants
|
|||
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H17Cl2N
|
|||
| Canonical SMILES |
CNC1CCC(C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl
|
|||
| InChI |
1S/C17H17Cl2N/c1-20-17-9-7-12(13-4-2-3-5-14(13)17)11-6-8-15(18)16(19)10-11/h2-6,8,10,12,17,20H,7,9H2,1H3/t12-,17-/m0/s1
|
|||
| InChIKey |
VGKDLMBJGBXTGI-SJCJKPOMSA-N
|
|||
| CAS Number |
CAS 79617-96-2
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9455, 7849419, 7980593, 8192230, 11372017, 11374862, 11484121, 11488309, 11490894, 11493046, 14776364, 14923174, 17425146, 24723455, 26753299, 29215139, 43125164, 46505341, 47870036, 48019284, 48243732, 48394276, 48416536, 49665783, 49699249, 49995188, 50105682, 50105683, 50105684, 50105685, 50723729, 53788480, 57288837, 57316967, 57654971, 85148370, 85789675, 90341218, 92714411, 93166926, 93167211, 99445038, 103213015, 103937473, 104342622, 117463757, 117475932, 118047120, 121264488, 121363704
|
|||
| ChEBI ID |
CHEBI:9123
|
|||
| ADReCS Drug ID | BADD_D02010 ; BADD_D02011 | |||
| SuperDrug ATC ID |
N06AB06
|
|||
| SuperDrug CAS ID |
cas=079617962
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Prevotella copri
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Prevotella copri was decreased by Sertraline (adjusted p-values: 2.80E-03). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Eubacterium eligens
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium eligens was decreased by Sertraline (adjusted p-values: 8.31E-03). | |||
|
Studied Microbe: Eubacterium rectale
Show/Hide Hierarchy
|
[3] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Eubacterium rectale was decreased by Sertraline (adjusted p-values: 1.55E-03). | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Serotonin transporter (SERT) | Target Info | Inhibitor | [4], [5] |
| KEGG Pathway | Serotonergic synapse | |||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | 5HT1 type receptor mediated signaling pathway | |||
| 5HT2 type receptor mediated signaling pathway | ||||
| 5HT3 type receptor mediated signaling pathway | ||||
| 5HT4 type receptor mediated signaling pathway | ||||
| WikiPathways | Monoamine Transport | |||
| SIDS Susceptibility Pathways | ||||
| NRF2 pathway | ||||
| Synaptic Vesicle Pathway | ||||
| Serotonin Transporter Activity | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4798). | |||
| REF 2 | Emerging treatments for depression. Expert Opin Pharmacother. 2006 Dec;7(17):2323-39. | |||
| REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 4 | Psychopharmacological treatment of dermatological patients--when simply talking does not help. J Dtsch Dermatol Ges. 2007 Dec;5(12):1101-6. | |||
| REF 5 | Methadone: from pharmacokinetic profile to clinical pharmacology. Encephale. 2006 Jul-Aug;32(4 Pt 1):478-86. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.